Search
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
… ces-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas … On … 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients …
FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer
… -information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer … On May 4, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) …
FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
… roved-drugs/fda-disco-burst-edition-enhertu-fam-trastuzumab-deruxtecan-nxki-and-combination-opdivo-nivolumab-and … … drug approvals. On January 15, 2021, FDA approved fam-trastuzumab deruxtecan-nxki (brand name Enhertu) for adult patients with …
FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
… Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU®, Daiichi Sankyo) for patients with … or more prior anti-HER2 therapies. Patients received fam-trastuzumab deruxtecan-nxki 5.4 mg/kg by intravenous infusion …
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer
… drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer … On August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) …
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
… ormation-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung … On August … Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) …
FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive breast cancer
… oved-drugs/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-adult-patients … Podcast Welcome back to the … cancer drug approval. On May 4, 2022, the FDA approved fam-trastuzumab deruxtecan-nxki (brand name Enhertu) for adult …
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
… ormation-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 … On April 5, … Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) …
FDA D.I.S.C.O. Burst Edition: FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer and Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-mutant non-small cell lung cancer
… 11, 2022, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (brand name Enhertu) for adult patients with … metastatic non-small cell lung cancer, and Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic …
FDA D.I.S.C.O. Burst Edition: FDA approvals of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, and Nubeqa (darolutamide) in combination with docetaxel for metastatic hormone-sensitive prostate cancer
… ved-drugs/fda-disco-burst-edition-fda-approvals-enhertu-fam-trastuzumab-deruxtecan-nxki-unresectable-or … Podcast Welcome back to the … drug approvals. On August 5, 2022, the FDA approved fam-trastuzumab deruxtecan-nxki (brand name Enhertu) for adult …
Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
… (zanubrutinib) FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) … Burst Edition: Tabrecta (capmatinib) and Enhertu (fam-trastuzumab deruxtecan-nxki) FDA approvals of Tabrecta (capmatinib) for …
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
… test. 4/18/2024 FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive … Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) …
Ongoing | Cancer Accelerated Approvals
… Requirement Original Projected Completion 1 Enhertu (fam-trastuzumab deruxtecan-nxki) Adult patients with unresectable or … 12/31/2026 Tukysa (tucatinib) In combination with trastuzumab for the treatment of adult patients with RAS …
Table of Pharmacogenomic Biomarkers in Drug Labeling
… Reactions, Clinical Pharmacology, Clinical Studies Ado-Trastuzumab Emtansine Oncology ERBB2 (HER2) Indications and … Usage, Dosage and Administration, Clinical Studies Fam-Trastuzumab Deruxtecan-nxki (1) Oncology ERBB2 (HER2) Indications and …
Verified Clinical Benefit | Cancer Accelerated Approvals
… least 2 prior regimens 12/28/2004 7/18/2022 Enhertu (Fam-trastuzumab deruxtecan-nxki) Adult patients with unresectable or … 11/20/2015 Perjeta (pertuzumab) In combination with trastuzumab and docetaxel for neoadjuvant treatment of …
New Drug Therapy Approvals 2019
… of larvae in contaminated water or food. Enhertu (fam-trastuzumab deruxtecan-nxki) injection, approved under FDA’s accelerated … post-thrombotic syndrome (damage to vein). Kadcyla (ado-trastuzumab emtansine) injection, originally approved in 2013 …
Novel Drug Approvals for 2019
… adults Press Release Drug Trials Snapshot 47. Enhertu fam-trastuzumab deruxtecan-nxki 12/20/2019 To treat metastatic breast cancer …
What's New Related to Drugs
… April 5, 2024 FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive …
Drug Trials Snapshot: ENHERTU
… Package Insert for complete information. ENHERTU (fam-trastuzumab deruxtecan-nxki) (en HER too) Daiichi Sankyo, Inc. Approval …
Drug Trials Snapshots
… 2015 Treatment of multiple myeloma Empliciti ENHERTU fam-trastuzumab deruxtecan-nxki December 20, 2019 Metastatic HER2-positive …
New Drug Therapy Approvals 2022
… the first approved therapy for this disorder. Enhertu (fam-trastuzumab deruxtecan-nxki) intravenous infusion was originally approved …